REGN: Rounding Bottom detected on 17 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 45 setups from the 17 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 17 Nov 2026, our scan flagged REGN as a rounding bottom setup scoring 75 out of 98 (Good tier), with a 76% win probability based on our historical pattern database and a 0.63 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $952.40, the conservative target is $1000.40 with a stop at $875.68.

75 of 98
Good
76%
High
0.63 : 1
$48.00 to target $76.72 to stop
Swing Trading Plan
Entry
$952.40
$1000.40
$875.68
2-8 trading days
+$12.48
Exp. Reward
+$29.00
Exp. Risk
-$16.52

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
REGN is forming a rounding_bottom pattern at $952.40, nearly 4% below its 52-week high and 61% above its 52-week low. The structure score of 15.0/15 indicates textbook formation quality, with strong breakout mechanics (13.0/13) but softer volume confirmation (10.15/12 relative to baseline). The pattern sits 23% above key support at $590.83 and faces primary resistance at $764.67. RSI of 67.46 shows late-stage bullish momentum without overextension, while positive MACD histogram (3.99) supports upside structure. Overall score of 75.15 reflects high conviction, with 75.8% win probability suggesting strong historical follow-through on comparable setups.
Stock Context
Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025, driven by accelerating blockbuster performance. Dupixent global net sales increased 35% to $6.5 billion, EYLEA HD U.S. net sales increased 62% to $699 million, and Libtayo global net sales increased 51% to $550 million. The company expanded collaboration with Sanofi, with $1.0 billion up-front recognized in Q4 2026 and potential to receive up to an additional $7.0 billion in future milestones. Pasatru (garetosmab) received FDA approval for fibrodysplasia ossificans progressiva. The rounding bottom forms post-earnings euphoria, with management emphasis on 50-asset pipeline suggesting sustained growth narrative driving continuation higher.
What to Expect
A successful breakout above $764.67 resistance would target the conservative measure move of $1000.40, representing a 5% gain from current price. Volume confirmation is critical—historical rounding bottom breakouts require sustained volume above the recent 20-day average of 1.02M shares. Current volume at 701k (69% of average) suggests potential near-term testing of resistance before decisive breakout. Invalidation occurs below key support at $590.83, a 38% decline. With 75.8% win probability, the pattern indicates favoring upside, though the weak volume ratio (0.69) during the rounding formation suggests breakout volume will be crucial for successful follow-through.
Risk Factors
Cemdisiran awaits generalized myasthenia gravis decision in November 2026, creating near-term binary event risk. Earnings strength is concentrated in three franchises—Dupixent, EYLEA HD, and Libtayo—so concentration risk has not been reduced. Multiple biosimilar versions of original Eylea are entering the U.S. market, expected to further decline 2H 2026 sales. RSI at 67.46 approaches overbought conditions (>70), signaling potential pullback risk in a bearish market regime (regime score -0.56) despite sector tailwinds. Notably, volume is 31% below 20-day average, reducing breakout conviction. High beta inversion (-0.09) means REGN may underperform in broader market weakness.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is REGN a good swing trade?
REGN scored 75 out of 98 on our rounding bottom scan, with a 76% historical win probability over a 2-8 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $952.40, with a conservative target of $1000.40 and a stop loss at $875.68.
What would invalidate this rounding bottom setup?
A close below the stop loss at $875.68 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical rounding bottom setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bearish -0.57
-1.0 0 +1.0
Health Care Sector
Bullish 0.89
-1.0 0 +1.0
Other Patterns Detected Today
Bull Flag
29 days in pattern
Weak 22.4
Overall Score
38 of 40
Exceptional
Pattern Quality
14 of 20
Good
Setup
13 of 20
Moderate
R/R
10 of 18
Fair
Context
Pattern Quality Score
15 of 15
Exceptional
Structure
13 of 13
Exceptional
Breakout
10 of 12
Strong
Volume
Recent Performance
+3.5%
1W
-0.9%
2W
+20.4%
1M
+17.6%
3M
Momentum & Trend
RSI (14)
67.5
Neutral
MACD Histogram
+3.99
Strong Bullish
Bollinger Band Position
74.6%
Upper Zone
Volatility & Risk
20-Day Volatility
0.57
Very High
ATR %
4.1%
Medium
Beta
-0.09
Defensive
Volume Analysis
Volume Ratio
0.69x
Below Avg
20-Day Avg Vol
1.0M
shares / day
Current Volume
701K
shares traded
Price Levels
Target
$1000.40
52W High
$991.77
Current
$952.40
Stop Loss
$875.68
Resistance
$764.67
Support
$590.83
52W Low
$590.82
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.